SMS Pharma clears USFDA inspection at Vizag facility with minor observation

Regulatory & Legal View source PDF Explain this filing

SMSPHARMA · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+1.4%Reaction day

₹320.15

prior close

₹325.00

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used+0.5%+0.9% vs market

Pharmaceuticals peers, median of 155sector-0.1%+1.5% vs sector

On the reaction day the stock moved 0.9 pts more than Nifty Microcap 250 and 1.5 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-0.3

10m

-0.7

15m

-1.2

30m

-1.0

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+1.4+0.5+0.9-0.1+1.5

Next day

-1.3-0.1-1.2-0.6-0.7

-4.0-1.0-2.9-1.3-2.7

-4.8-1.3-3.4-1.4-3.4

-2.6-0.1-2.5-0.6-2.0

-1.6+1.3-2.9+0.0-1.6

-2.6+0.8-3.4-0.0-2.6

15d

+6.6+1.5+5.1+0.7+5.9

+3.9-3.0+6.9-2.8+6.7

+6.0-2.8+8.8-4.9+10.9

+14.5-12.4+26.9-10.9+25.4

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 155Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

SMS Pharmaceuticals announced successful completion of USFDA inspection at its 3,000 KL API manufacturing facility in Visakhapatnam, conducted December 8 to 12, 2025. The inspection ended with one minor procedural observation in Form 483, with no data integrity concerns. The company will respond within the stipulated time. This was the 4th inspection at the Vizag facility and the 12th across all manufacturing sites.

Likely market impact

Positive for the stock. Confirms regulatory compliance, supports continued API exports to the US. No material impact from the minor observation.